Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: pemetrexed
Drug: irinotecan

First Posted Date: 2005-09-19

Last Posted Date: 2011-01-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 46

Registration Number: NCT00191984

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Suresnes, France

Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2012-03-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00182806

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

Phase 1

Completed

Conditions: Pancreatic Cancer
Gastric Cancer
Duodenum Cancer
Bile Duct Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 22

Registration Number: NCT00183846

Locations: 🇺🇸
U.S.C./Norris Cancer Center, Los Angeles, California, United States

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Phase 1

Completed

Conditions: Gastric Cancer
Adenocarcinoma

Interventions: Drug: irinotecan

First Posted Date: 2005-09-16

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 42

Registration Number: NCT00183859

Locations: 🇺🇸
U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

Phase 2

Completed

Conditions: Colorectal Carcinoma

First Posted Date: 2005-09-15

Last Posted Date: 2012-02-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 24

Registration Number: NCT00176774

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: celecoxib
Drug: irinotecan
Procedure: concurrent radiotherapy

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-02

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 23

Registration Number: NCT00177853

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer
GE Junction Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00165464

Locations: 🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of Esophagus
Squamous Cell Carcinoma of Esophagus

First Posted Date: 2005-09-14

Last Posted Date: 2014-11-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00165490

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States